vs

Side-by-side financial comparison of Blue Hat Interactive Entertainment Technology (BHAT) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Blue Hat Interactive Entertainment Technology is the larger business by last-quarter revenue ($13.1M vs $12.5M, roughly 1.0× Avidity Biosciences, Inc.). Blue Hat Interactive Entertainment Technology runs the higher net margin — -9.9% vs -1398.3%, a 1388.4% gap on every dollar of revenue.

Blue Hat Interactive Entertainment Technology develops and produces interactive entertainment products including AR games, smart interactive toys, and immersive leisure content. It primarily serves mainland China's consumer market, with expanding distribution across Southeast Asia, focusing on family and youth entertainment segments.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

BHAT vs RNA — Head-to-Head

Bigger by revenue
BHAT
BHAT
1.0× larger
BHAT
$13.1M
$12.5M
RNA
Higher net margin
BHAT
BHAT
1388.4% more per $
BHAT
-9.9%
-1398.3%
RNA

Income Statement — Q2 FY2025 vs Q3 FY2025

Metric
BHAT
BHAT
RNA
RNA
Revenue
$13.1M
$12.5M
Net Profit
$-1.3M
$-174.4M
Gross Margin
8.3%
Operating Margin
-9.4%
-1513.5%
Net Margin
-9.9%
-1398.3%
Revenue YoY
434.0%
Net Profit YoY
-117.0%
EPS (diluted)
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BHAT
BHAT
RNA
RNA
Q3 25
$12.5M
Q2 25
$13.1M
$3.8M
Q1 25
$1.6M
Q4 24
$3.0M
Q3 24
$2.3M
Q2 24
$46.3M
$2.0M
Q1 24
$3.5M
Q4 23
$2.2M
Net Profit
BHAT
BHAT
RNA
RNA
Q3 25
$-174.4M
Q2 25
$-1.3M
$-157.3M
Q1 25
$-115.8M
Q4 24
$-102.3M
Q3 24
$-80.4M
Q2 24
$-4.4M
$-70.8M
Q1 24
$-68.9M
Q4 23
$-60.4M
Gross Margin
BHAT
BHAT
RNA
RNA
Q3 25
Q2 25
8.3%
Q1 25
Q4 24
Q3 24
Q2 24
0.2%
Q1 24
Q4 23
Operating Margin
BHAT
BHAT
RNA
RNA
Q3 25
-1513.5%
Q2 25
-9.4%
-4448.7%
Q1 25
-8360.9%
Q4 24
-4069.6%
Q3 24
-4200.9%
Q2 24
-8.8%
-4040.4%
Q1 24
-2178.6%
Q4 23
-3043.5%
Net Margin
BHAT
BHAT
RNA
RNA
Q3 25
-1398.3%
Q2 25
-9.9%
-4089.3%
Q1 25
-7360.0%
Q4 24
-3439.5%
Q3 24
-3441.7%
Q2 24
-9.4%
-3461.8%
Q1 24
-1943.4%
Q4 23
-2756.2%
EPS (diluted)
BHAT
BHAT
RNA
RNA
Q3 25
$-1.27
Q2 25
$-1.21
Q1 25
$-0.90
Q4 24
$-0.80
Q3 24
$-0.65
Q2 24
$-0.65
Q1 24
$-0.79
Q4 23
$-0.80

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BHAT
BHAT
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$14.3K
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$32.1M
$1.9B
Total Assets
$75.2M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BHAT
BHAT
RNA
RNA
Q3 25
$350.2M
Q2 25
$14.3K
$243.9M
Q1 25
$254.2M
Q4 24
$219.9M
Q3 24
$370.2M
Q2 24
$407.6K
$575.8M
Q1 24
$471.4M
Q4 23
$185.1M
Stockholders' Equity
BHAT
BHAT
RNA
RNA
Q3 25
$1.9B
Q2 25
$32.1M
$1.2B
Q1 25
$1.3B
Q4 24
$1.4B
Q3 24
$1.5B
Q2 24
$40.6M
$1.2B
Q1 24
$830.9M
Q4 23
$500.8M
Total Assets
BHAT
BHAT
RNA
RNA
Q3 25
$2.1B
Q2 25
$75.2M
$1.4B
Q1 25
$1.5B
Q4 24
$1.6B
Q3 24
$1.6B
Q2 24
$49.3M
$1.3B
Q1 24
$951.5M
Q4 23
$628.6M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BHAT
BHAT
RNA
RNA
Operating Cash FlowLast quarter
$2.6M
$-156.2M
Free Cash FlowOCF − Capex
$-156.9M
FCF MarginFCF / Revenue
-1257.6%
Capex IntensityCapex / Revenue
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BHAT
BHAT
RNA
RNA
Q3 25
$-156.2M
Q2 25
$2.6M
$-199.7M
Q1 25
$-124.8M
Q4 24
$-99.9M
Q3 24
$-65.6M
Q2 24
$-65.0M
Q1 24
$-70.4M
Q4 23
$16.5M
Free Cash Flow
BHAT
BHAT
RNA
RNA
Q3 25
$-156.9M
Q2 25
$-203.0M
Q1 25
$-128.6M
Q4 24
$-103.8M
Q3 24
$-67.3M
Q2 24
$-65.5M
Q1 24
$-71.3M
Q4 23
$15.6M
FCF Margin
BHAT
BHAT
RNA
RNA
Q3 25
-1257.6%
Q2 25
-5277.1%
Q1 25
-8174.3%
Q4 24
-3491.0%
Q3 24
-2881.8%
Q2 24
-3204.6%
Q1 24
-2012.3%
Q4 23
713.1%
Capex Intensity
BHAT
BHAT
RNA
RNA
Q3 25
5.7%
Q2 25
86.9%
Q1 25
238.6%
Q4 24
131.7%
Q3 24
72.9%
Q2 24
26.0%
Q1 24
25.8%
Q4 23
39.4%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons